Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept

Completed

Conditions studied: Age-Related Macular Degeneration

In brief

A cohort of patients responsive to treatment with ranibizumab but resistant to aflibercept were identified in a previously conducted retrospective study. Identified patients will have their blood drawn for genome wide sequencing. The sequencing data will be compiled and analyzed in an attempt to identify a common genetic basis for patients susceptible to ranibizumab but resistant to aflibercept.

Key facts

Study ID

NCT02291887

Run by

Associated Retinal Consultants, Michigan

People needed

13

Starts

2014-12-22

Expected to finish

2015-07-01

Last updated by the study team

2017-11-17

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subjects will be eligible if the following criteria are met:
• Demonstrate worsening of exudation when switched from ranibizumab to aflibercept
• Ability to provide written informed consent and comply with study assessments for the full duration of the study

You may not qualify if…

• Any other condition that the investigator believes would pose a significant hazard to the subject

Where it is running

• Associated Retinal Consultants — Royal Oak, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.